Clinical trials: Lymphangiectasia
Lymphangiomatosis, Lymphedema
Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Background: Lymphatics are a type of vessel, similar to arteries and veins. Lymphatic disorders happen when these vessels don t work properly.
- Conditions
- Lymphangiomatosis, Lymphedema, Lymphangiectasia, Pulmonary Lymphangiectasia
- Trial name
- NCT02156115
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphedema
International Lymphatic Disease and Lymphedema Registry
The purpose of the International Lymphatic Disease and Lymphedema Patient Registry and Biorepository is to collect health information in order to study the disease classification, natural history, and impact of Lymphatic Disease…
- Trial name
- NCT01336790
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Stanford University
Lymphatic Diseases, Lymphatic Abnormalities
A Prospective Natural History Study of Lymphatic Anomalies
Background: The lymphatic system is a network of vessels that carry a clear fluid called lymph through the body. Problems in the lymphatic system can cause pain, fluid buildup, and issues with immunity.
- Trial name
- NCT05731141
- Where
- 2 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Kaposiform Hemangioendotheliomas, Tufted Angioma
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved…
- Conditions
- Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation
- Trial name
- NCT00975819
- Testing
- sirolimus
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Denise Martin Adams
CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis
Transcriptome and Metabolic Analyses of CHAPLE Disease
CHAPLE syndrome (complement hyperactivation, angiopathic thrombosis, protein losing enteropathy) is a newly discovered genetic disorder, which is caused by deleterious mutations in the CD55 gene.
- Conditions
- CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis, Protein-Losing Enteropathies, Complement Regulatory Factor Defect
- Trial name
- CHAPLEOMIC (NCT03950804)
- Testing
- Eculizumab Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marmara University